Can a Patient with Multiple Myeloma Take Leqvio?
Yes, a patient with multiple myeloma can safely take Leqvio (inclisiran) for LDL-cholesterol lowering, as there are no contraindications or drug interactions between inclisiran and multiple myeloma therapies.
Key Clinical Reasoning
The available evidence shows no overlap between inclisiran's mechanism of action and multiple myeloma treatment pathways:
Inclisiran's mechanism: A small interfering RNA (siRNA) that targets hepatic PCSK9 mRNA production, administered subcutaneously every 6 months after initial loading doses 1, 2
Multiple myeloma therapies: Include proteasome inhibitors (bortezomib, carfilzomib), immunomodulatory drugs (lenalidomide, pomalidomide), monoclonal antibodies (daratumumab, elotuzumab), and corticosteroids 3, 4, 5
No documented interactions: None of the NCCN guidelines for multiple myeloma 3, 4, 5 or the Mayo Clinic recommendations 6 mention any contraindications or precautions regarding lipid-lowering therapies including PCSK9 inhibitors
Important Clinical Considerations
Cardiovascular Risk in Multiple Myeloma Patients
Multiple myeloma patients often have elevated cardiovascular risk due to:
- Disease-related factors (hyperviscosity, amyloidosis)
- Treatment-related cardiotoxicity, particularly with carfilzomib (hypertension in 12.2%, heart failure in 4.1%, ischemic heart disease in 1.8%) 7
- Thrombotic risk from immunomodulatory drugs requiring anticoagulation 3, 4, 8
This makes aggressive LDL-C lowering particularly important in this population.
Practical Management Algorithm
Assess baseline cardiovascular status before starting myeloma therapy, especially if carfilzomib is planned 7
Initiate or optimize statin therapy as first-line lipid management
Add inclisiran if:
Dosing: 284 mg subcutaneously at Day 1, Day 90, then every 6 months 1, 2
Monitor: LDL-C reduction of 44-50% expected by Day 150-210, sustained through 4+ years 11, 12
Safety Profile
Inclisiran demonstrates excellent safety across diverse populations 11, 13, 14, 12:
- Main adverse effect: injection site reactions (5.9-14%)
- No hepatic, renal, or muscle toxicity signals
- Anti-drug antibodies rare (4.6-5.5%) and clinically insignificant
- No drug-drug interactions requiring dose adjustment
Specific Myeloma Treatment Considerations
No dose adjustments needed when combining inclisiran with:
- Proteasome inhibitors (bortezomib, carfilzomib, ixazomib)
- Immunomodulatory drugs (lenalidomide, pomalidomide, thalidomide)
- Monoclonal antibodies (daratumumab, elotuzumab)
- Corticosteroids (dexamethasone)
Continue standard myeloma supportive care:
- Anticoagulation for immunomodulatory drugs (aspirin or therapeutic anticoagulation) 3, 4, 8
- Herpes zoster prophylaxis for proteasome inhibitors 4
- Bisphosphonates for bone disease 3
Clinical Pitfalls to Avoid
Don't delay lipid management: Cardiovascular disease is a significant cause of morbidity/mortality in myeloma patients, particularly those receiving cardiotoxic agents like carfilzomib 7
Don't assume statin intolerance: Inclisiran works effectively as monotherapy in statin-intolerant patients 14, but most myeloma patients can tolerate some statin therapy
Don't overlook renal function: While inclisiran has no renal dose adjustment requirements 1, many myeloma patients have renal insufficiency requiring careful monitoring of all medications